Hypoxia‐induced chemoresistance remains a major obstacle to treating osteosarcoma
effectively. Mxd1, a member of the Myc/Max/Mxd family, was shown to be involved in the …

Abstract Activation of PI3K/AKT signalling by PTEN loss significantly enhances
chemoresistance in bladder cancer. This study aims to evaluate PTEN regulation and …

Chemoresistance is the main obstacle in the clinical treatment of osteosarcoma (OS). In this
study, we investigated the role of EF-hand domain-containing protein 1 (EFHD1) in OS …

Abstract Maternally expressed gene 3 (Meg3) has been shown to promote tumor
progression. However, the role of Meg3 in the development of a chemoresistant phenotype …

Objective Cisplatin is the first-line treatment for breast cancer, but it faces challenges of drug
resistance. This study investigated new molecular mechanisms underlying cisplatin …

Background Non-small cell lung cancer (NSCLC) is one of the most aggressive types of
cancer. However, resistance to cisplatin (CDDP) remains a major challenge in NSCLC …

Colorectal cancer (CRC) driven by PTEN deficiency exhibits high risk of metastasis,
advancement of tumor stages and chemotherapy resistance, where no effective therapy has …

Oxaliplatin is widely used in the frontline treatment of colorectal cancer (CRC), but an
estimated 50% of patients will eventually stop responding to treatment due to acquired …

Osteosarcoma (OS) is the most common bone malignant tumor. However, the genetic basis
of OS pathogenesis is still not understood, and occurrence of chemo-resistance is a major …

Tumor hypoxia has been reported to be a negative prognostic factor in a number of tumor
sites. Both clinical and experimental studies have suggested a positive correlation between …